UK drug regulator to restart inspections at the end of March with a focus on social distancing
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) said Friday that it will restart its onsite inspections of drug manufacturing sites on March 29.
MHRA made clear that the onsite inspections, which had been suspended since Jan. 5, will only occur at sites that have been notified at least two weeks in advance unless there are public health reasons that require shorter notice or unannounced inspections. The regulator also said it will ensure limited face-to-face interactions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.